Latest Biotech News

Page 24 of 33
Tissue Repair Limited has secured major distribution partnerships in Australia, New Zealand, and Thailand for its TR Pro+® product line, marking a pivotal shift from development to commercialisation. The company is also scaling up manufacturing and advancing regulatory approvals to support its global expansion ambitions.
Ada Torres
Ada Torres
11 July 2025
Neurizon Therapeutics has received positive feedback from the FDA on its plan to resolve the clinical hold on its ALS drug candidate NUZ-001, with key preclinical studies completed ahead of schedule. The company aims to resume clinical trials in late 2025.
Ada Torres
Ada Torres
10 July 2025
Terragen Holdings has been granted a US patent for its microbial feed supplements, reinforcing its position in the animal probiotics market and supporting plans for US market entry.
Ada Torres
Ada Torres
3 July 2025
Prescient Therapeutics has opened a Share Purchase Plan to raise up to $7 million, offering shareholders discounted shares to fund the Phase 2 development of its targeted cancer therapy PTX-100.
Ada Torres
Ada Torres
2 July 2025
Neurizon Therapeutics has inked a pivotal global licensing deal with Elanco Animal Health, unlocking critical intellectual property and data to accelerate the development and commercialisation of its lead drug candidate NUZ-001 for neurodegenerative diseases including ALS.
Ada Torres
Ada Torres
2 July 2025
Prescient Therapeutics has launched a $7 million Share Purchase Plan at a notable discount to fund the next phase of clinical trials for its promising PTX-100 cancer therapy. The capital raise aims to accelerate progress toward regulatory approval and patient access.
Ada Torres
Ada Torres
1 July 2025
Paradigm Biopharmaceuticals has locked in a $27 million USD convertible note facility to fully fund its pivotal Phase 3 trial for knee osteoarthritis, ensuring operational momentum through key clinical milestones.
Ada Torres
Ada Torres
1 July 2025
Rhythm Biosciences has obtained a $1 million non-dilutive loan backed by its FY2025 R&D Tax Incentive rebate, aiming to accelerate the commercial rollout of its ColoSTAT® test and expand its geneType™ platform.
Ada Torres
Ada Torres
30 June 2025
Actinogen Medical has locked in up to $13.8 million in non-dilutive funding tied to its R&D tax incentives, bolstering its cash position as it advances a pivotal Alzheimer’s disease clinical trial.
Ada Torres
Ada Torres
30 June 2025
Actinogen Medical has enrolled its 100th participant in the XanaMIA phase 2b/3 Alzheimer’s trial, setting the stage for a critical interim analysis in January 2026 and final results by year-end.
Ada Torres
Ada Torres
30 June 2025
Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology monoclonal antibody targeting VISTA, from Hummingbird Bioscience, marking a strategic pivot after recent setbacks. The company plans to initiate phase II trials in 2026, aiming to advance this novel cancer therapy toward commercialisation.
Ada Torres
Ada Torres
26 June 2025
INOVIQ Limited has responded to ASX queries defending its announcement that its new CAR-NK-EV treatment killed 88% of breast and lung cancer cells in vitro, confirming compliance with disclosure rules and providing detailed study data.
Ada Torres
Ada Torres
23 June 2025